119 related articles for article (PubMed ID: 36580346)
1. Structure-Based Design of the Indole-Substituted Triazolopyrimidines as New EED-H3K27me3 Inhibitors for the Treatment of Lymphoma.
Dong G; Zuo J; Yu J; Xu J; Gao G; Li GB; Zhao W; Yu B
J Med Chem; 2023 Jan; 66(1):1063-1081. PubMed ID: 36580346
[TBL] [Abstract][Full Text] [Related]
2. EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development.
Rej RK; Wang C; Lu J; Wang M; Petrunak E; Zawacki KP; McEachern D; Fernandez-Salas E; Yang CY; Wang L; Li R; Chinnaswamy K; Wen B; Sun D; Stuckey J; Zhou Y; Chen J; Tang G; Wang S
J Med Chem; 2020 Jul; 63(13):7252-7267. PubMed ID: 32580550
[TBL] [Abstract][Full Text] [Related]
3. An Allosteric PRC2 Inhibitor Targeting EED Suppresses Tumor Progression by Modulating the Immune Response.
Dong H; Liu S; Zhang X; Chen S; Kang L; Chen Y; Ma S; Fu X; Liu Y; Zhang H; Zou B
Cancer Res; 2019 Nov; 79(21):5587-5596. PubMed ID: 31395608
[TBL] [Abstract][Full Text] [Related]
4. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.
Cook N; Chen J; Zhou J; Wu D
Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341
[TBL] [Abstract][Full Text] [Related]
5. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-323-3p regulates the activity of polycomb repressive complex 2 (PRC2) via targeting the mRNA of embryonic ectoderm development (Eed) gene in mouse embryonic stem cells.
Zhang Y; Teng F; Luo GZ; Wang M; Tong M; Zhao X; Wang L; Wang XJ; Zhou Q
J Biol Chem; 2013 Aug; 288(33):23659-65. PubMed ID: 23821546
[TBL] [Abstract][Full Text] [Related]
7. PICOT binding to the polycomb group protein, EED, alters H3K27 methylation at the MYT1 PRC2 target gene.
Pandya P; Pasvolsky R; Babichev Y; Braiman A; Witte S; Altman A; Isakov N
Biochem Biophys Res Commun; 2019 Feb; 509(2):469-475. PubMed ID: 30595380
[TBL] [Abstract][Full Text] [Related]
8. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
[TBL] [Abstract][Full Text] [Related]
9. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
[TBL] [Abstract][Full Text] [Related]
10. Binding Modes of Small-Molecule Inhibitors to the EED Pocket of PRC2.
Huang D; Tian S; Qi Y; Zhang JZH
Chemphyschem; 2020 Feb; 21(3):263-271. PubMed ID: 31816138
[TBL] [Abstract][Full Text] [Related]
11. EED orchestration of heart maturation through interaction with HDACs is H3K27me3-independent.
Ai S; Peng Y; Li C; Gu F; Yu X; Yue Y; Ma Q; Chen J; Lin Z; Zhou P; Xie H; Prendiville TW; Zheng W; Liu Y; Orkin SH; Wang DZ; Yu J; Pu WT; He A
Elife; 2017 Apr; 6():. PubMed ID: 28394251
[TBL] [Abstract][Full Text] [Related]
12. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
13. Polycomb protein EED is required for silencing of pluripotency genes upon ESC differentiation.
Obier N; Lin Q; Cauchy P; Hornich V; Zenke M; Becker M; Müller AM
Stem Cell Rev Rep; 2015 Feb; 11(1):50-61. PubMed ID: 25134795
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.
Li L; Zhang H; Zhang M; Zhao M; Feng L; Luo X; Gao Z; Huang Y; Ardayfio O; Zhang JH; Lin Y; Fan H; Mi Y; Li G; Liu L; Feng L; Luo F; Teng L; Qi W; Ottl J; Lingel A; Bussiere DE; Yu Z; Atadja P; Lu C; Li E; Gu J; Zhao K
PLoS One; 2017; 12(1):e0169855. PubMed ID: 28072869
[TBL] [Abstract][Full Text] [Related]
15. Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2).
Xu C; Bian C; Yang W; Galka M; Ouyang H; Chen C; Qiu W; Liu H; Jones AE; MacKenzie F; Pan P; Li SS; Wang H; Min J
Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19266-71. PubMed ID: 20974918
[TBL] [Abstract][Full Text] [Related]
16. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.
He Y; Selvaraju S; Curtin ML; Jakob CG; Zhu H; Comess KM; Shaw B; The J; Lima-Fernandes E; Szewczyk MM; Cheng D; Klinge KL; Li HQ; Pliushchev M; Algire MA; Maag D; Guo J; Dietrich J; Panchal SC; Petros AM; Sweis RF; Torrent M; Bigelow LJ; Senisterra G; Li F; Kennedy S; Wu Q; Osterling DJ; Lindley DJ; Gao W; Galasinski S; Barsyte-Lovejoy D; Vedadi M; Buchanan FG; Arrowsmith CH; Chiang GG; Sun C; Pappano WN
Nat Chem Biol; 2017 Apr; 13(4):389-395. PubMed ID: 28135237
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal.
Turner AW; Dronamraju R; Potjewyd F; James KS; Winecoff DK; Kirchherr JL; Archin NM; Browne EP; Strahl BD; Margolis DM; James LI
ACS Infect Dis; 2020 Jul; 6(7):1719-1733. PubMed ID: 32347704
[TBL] [Abstract][Full Text] [Related]
18. Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.
Huang Y; Sendzik M; Zhang J; Gao Z; Sun Y; Wang L; Gu J; Zhao K; Yu Z; Zhang L; Zhang Q; Blanz J; Chen Z; Dubost V; Fang D; Feng L; Fu X; Kiffe M; Li L; Luo F; Luo X; Mi Y; Mistry P; Pearson D; Piaia A; Scheufler C; Terranova R; Weiss A; Zeng J; Zhang H; Zhang J; Zhao M; Dillon MP; Jeay S; Qi W; Moggs J; Pissot-Soldermann C; Li E; Atadja P; Lingel A; Oyang C
J Med Chem; 2022 Apr; 65(7):5317-5333. PubMed ID: 35352560
[TBL] [Abstract][Full Text] [Related]
19. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
Yang CY; Wang S
J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
[TBL] [Abstract][Full Text] [Related]
20. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.
Hsu JH; Rasmusson T; Robinson J; Pachl F; Read J; Kawatkar S; O' Donovan DH; Bagal S; Code E; Rawlins P; Argyrou A; Tomlinson R; Gao N; Zhu X; Chiarparin E; Jacques K; Shen M; Woods H; Bednarski E; Wilson DM; Drew L; Castaldi MP; Fawell S; Bloecher A
Cell Chem Biol; 2020 Jan; 27(1):41-46.e17. PubMed ID: 31786184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
